A Study of QLS5133 Monotherapy in Advanced Solid Tumors
NCT07061639
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
212
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Interventions
DRUG:
QLS5133
Sponsor
Qilu Pharmaceutical Co., Ltd.